Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of September 2025. The filing details a share repurchase executed on September 9, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased (Sept 9, 2025): 207,767 ordinary shares.
- Price Range: Lowest 1,468.50p; Highest 1,490.50p.
- Volume-Weighted Average Price: 1,483.93p.
- Trading Venue: London Stock Exchange (XLON).
- Cumulative Buyback (since June 4, 2025): 28,019,060 ordinary shares.
- Treasury Shares Held: 246,153,443 ordinary shares.
- Shares in Issue (excluding Treasury): 4,069,248,284 ordinary shares.
- Treasury Voting Rights: 6.05% of total voting rights.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the September 9 transaction and the cumulative activity since June 4, 2025.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding future earnings or operational strategy. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q2 Results for 2025.
Important Facts for Investor Verification
- Verify the total number of voting rights (4,069,248,284) to determine notification thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the current percentage of voting rights held in treasury (6.05%) for corporate governance analysis.
- Review the cumulative buyback volume (28,019,060 shares) to assess the progress of the existing buyback programme initiated in June 2025.
- Note that this filing does not contain operational financial results; refer to Form 20-F or quarterly results for revenue and profit data.